共 50 条
Recent Progress of Src SH2 and SH3 Inhibitors as Anticancer Agents
被引:14
|作者:
Lu, X. -L.
[1
]
Cao, X.
[2
]
Liu, X. -Y.
[1
]
Jiao, B. -H.
[1
]
机构:
[1] Second Mil Med Univ, Dept Biochem & Mol Biol, Fac Basic Med Sci, Shanghai 200433, Peoples R China
[2] Chinese Acad Sci, Shanghai Inst Organ Chem, State Key Lab Bioorgan & Nat Prod Chem, Shanghai 200032, Peoples R China
关键词:
Protein tyrosine kinases;
Src kinases;
SH2;
SH3;
inhibitor;
peptidomimetic;
nonpeptide;
progress;
GROWTH-FACTOR RECEPTOR;
STRUCTURE-BASED DESIGN;
NONPEPTIDE INHIBITORS;
TYROSINE KINASE;
SMALL-MOLECULE;
ACTIVATED SRC;
LIGANDS;
CELL;
BINDING;
CANCER;
D O I:
10.2174/092986710790827861
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
Src family tyrosine kinases (SFKs) play key roles in regulating signal transduction in cellular processes. However, hyper-activated SFKs lead to uncontrolled cell proliferation and cancers. For both Src SH2 and SH3 domains involve in the regulation of tumorigenesis signal pathways, the SH2 and SH3 inhibition strategies are expected to block the protein-protein interactions between SFKs and their corporation proteins to abolish the signal transduction. Many inhibitors of SH2 and SH3 domain have been identified. Herein, some predominant examples of these inhibitors are reviewed.
引用
收藏
页码:1117 / 1124
页数:8
相关论文